Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies

Haemophilia. 2021 Nov;27(6):e772-e775. doi: 10.1111/hae.14421. Epub 2021 Oct 8.

Authors

Aric Parnes¹, Johnny N Mahlangu², Steven W Pipe³, Ido Paz-Priel⁴, Michaela Lehle⁵, Peter C Trask⁴, Víctor Jiménez-Yuste⁶

Affiliations

¹ Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
² University of the Witwatersrand and NHLS, Johannesburg, South Africa.
³ University of Michigan, Ann Arbor, Michigan, USA.
⁴ Genentech, Inc., South San Francisco, California, USA.
⁵ F. Hoffmann-La Roche Ltd., Basel, Switzerland.
⁶ La Paz University Hospital, Autónoma University, Madrid, Spain.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Bispecific*
Antibodies, Monoclonal, Humanized / therapeutic use
Factor VIII
Hemophilia A* / drug therapy
Humans
Patient Preference

Substances

Antibodies, Bispecific
Antibodies, Monoclonal, Humanized
emicizumab
Factor VIII